Nevro Reports Fourth Quarter and Full Year 2016 Financial Results and Provides 2017 Outlook

Nevro Reports Fourth Quarter and Full Year 2016 Financial
Results and Provides 2017 Outlook

Redwood City, Calif., February 23, 2017 - Nevro Corp. (NYSE: NVRO), a global medical device company
that is providing innovative evidence-based solutions for the treatment of chronic pain, today reported
financial results for the three months and full year ended December 31, 2016.
2016 Accomplishment & Highlights:

Achieved revenue of $228.5 million for the full year 2016, an increase of 228% as reported, over
the prior year
o U.S. revenue of $173.3 million for 2016, an increase of 612% over the prior year
o International revenue of $55.2 million for 2016, an increase of 26% in constant currency
and 22% on an as-reported basis, both over the prior year
Achieved revenue of $70.5 million in the fourth quarter of 2016, an increase of 113% as
reported, over the same period of the prior year
o U.S. revenue of $56.0 million for the fourth quarter of 2016, an increase of 183% over
the same period of the prior year
o International revenue of $14.5 million in the fourth quarter of 2016, an increase of 12%
in constant currency and 9% on an as-reported basis, both over the same period of the
prior year
Received U.S. Food & Drug Administration (FDA) approval for Surpass surgical leads for the
Senza Spinal Cord Stimulation (SCS) System
Raised gross proceeds of $172.5 million in public offering of convertible senior notes due 2021
before underwriting discounts and commissions and expenses
Publication of the 24-month SENZA-RCT results in Neurosurgery, the official Journal of the
Congress of Neurological Surgeons
Presented three-month data on twenty patients from Upper Limb and Neck (ULN) feasibility
study, showing an 83% responder rate in upper limb pain and 75% responder rate in neck pain,
demonstrating the continued robustness of HF10 therapy
Fourth Quarter Financial Results

Revenue for the quarter ended December 31, 2016 was $70.5 million versus $33.1 million during the
same period of the prior year, representing 113% growth as reported. U.S. revenue for the three months
ended December 31, 2016 was $56.0 million, representing 183% growth as reported. International
revenue was $14.5 million, representing growth of 12% in constant currency and 9% on an as-reported
basis. The increase in revenue was primarily attributable to the continued adoption of the Senza system.
Gross profit for the fourth quarter of 2016 was $48.8 million, representing a 69% gross margin, up from
$20.4 million, representing a 61% gross margin, in the same period of the prior year. Gross margins
increased year-over-year primarily due to fundamental cost improvements.
Operating expenses for the fourth quarter of 2016 were $55.1 million compared to $33.5 million in the
same period of the prior year, representing an increase of 65%. The increase in operating expenses was
driven primarily by increased headcount and related personnel costs, marketing programs, and clinical
trial and development expenses.
Loss from operations for the fourth quarter of 2016 was $6.3 million compared to $13.1 million for the
same period of the prior year.
Revenue Guidance for Full Year 2017

Nevro projects worldwide revenue for 2017 to be in the range of $310 to $320 million.
Webcast and Conference Call Information

Management will host a conference call today beginning at 1:30 p.m. PT / 4:30 p.m. ET. Individuals
interested in listening to the conference call may dial (877) 201-0168 for domestic callers, or (647) 788-
4901 for international callers (Conference ID: 65198382), or access the webcast on the Investors
section of the companys web site at: www.nevro.com/investors.
About Nevro
Headquartered in Redwood City, California, Nevro is a global medical device company focused on
providing innovative products that improve the quality of life of patients suffering from debilitating
chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system,
an evidence-based neuromodulation platform for the treatment of chronic pain. The Senza system is the
only SCS system that delivers Nevro's proprietary HF10 therapy. Senza, HF10, Nevro and the Nevro logo
are trademarks of Nevro.
Forward-Looking Statements
In addition to historical information, this press release contains forward-looking statements with respect
to our business, capital resources, revenue projections, strategic initiatives and growth, reflecting the
current beliefs and expectations of management made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995, including continuing adoption of, and interest in, Senza
in the U.S. and international markets; our plans for continued commercialization of Senza; our progress
towards becoming a leader in Neuromodulation; our positioning for sustained success; and our
expectations for worldwide revenue for the full year 2017. These forward-looking statements are based
upon information that is currently available to us or our current expectations, speak only as of the date
hereof, and are subject to numerous risks and uncertainties, including our ability to successfully
commercialize our products; our ability to manufacture our products to meet demand; the level and
availability of third-party payor reimbursement for our products; our ability to effectively manage our
anticipated growth; our ability to protect our intellectual property rights and proprietary technologies;
our ability to operate our business without infringing the intellectual property rights and proprietary
technology of third parties; competition in our industry; additional capital and credit availability; our
ability to attract and retain qualified personnel; and product liability claims. These factors, together with
those that are described in greater detail in our Annual Report on Form 10-K that we expect to file on
February 23, 2017, as well as any reports that we may file with the SEC in the future, may cause our
actual results, performance or achievements to differ materially and adversely from those anticipated or
implied by our forward-looking statements. We expressly disclaim any obligation, except as required by
law, or undertaking to update or revise any such forward-looking statements. Our results for the full year
and quarter ended December 31, 2016 are not necessarily indicative of our operating results for any
future periods.
Investor Relations Contact:

Nevro Investor Relations
Katherine Bock
(650) 433-3247
[email protected]
Nevro Corp.
Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share data)
Three Months Ended Year Ended

December 31, December 31,
2016 2015 2016 2015
(unaudited)
Revenue $ 70,531 $ 33,124 $ 228,504 $ 69,606
Cost of revenue 21,692 12,771 75,433 28,120
Gross profit 48,839 20,353 153,071 41,486
Operating expenses:
Research and development 11,276 5,874 33,729 21,382
Sales, general and administrative 43,832 27,623 142,423 82,471
Total operating expenses 55,108 33,497 176,152 103,853
Loss from operations (6,269 ) (13,144 ) (23,081 ) (62,367 )
Other income (expense):
Interest income (expense), net (1,780 ) (463 ) (4,709 ) (2,157 )
Other income (expense), net (1,193 ) 16 (1,097 ) (1,741 )
Loss on extinguishment of debt (1,268 )
Loss before income taxes (9,242 ) (13,591 ) (30,155 ) (66,265 )
Provision for income taxes 583 600 1,623 1,166
Net loss (9,825 ) (14,191 ) (31,778 ) (67,431 )
Changes in foreign currency translation
adjustment 283 13 (163 ) (178 )
Changes in unrealized losses on short-
term investments, net (44 ) (70 ) (340 ) (74 )
Net change in other comprehensive loss 239 (57 ) (503 ) (252 )
Comprehensive Loss $ (9,586 ) $ (14,248 ) $ (32,281 ) $ (67,683 )
Net loss per share, basic and diluted $ (0.34 ) $ (0.51 ) $ (1.12 ) $ (2.54 )
Weighted average shares used to compute
net loss per share, basic and diluted 28,817,333 28,003,957 28,485,003 26,581,890
Nevro Corp.
Consolidated Balance Sheets
(in thousands, except share and per share data)
December 31, December 31,

2016 2015
Assets
Current assets
Cash and cash equivalents $ 41,406 $ 87,036
Short-term investments 234,951 106,634
Accounts receivable, net 52,818 22,522
Inventories, net 85,221 62,430
Prepaid expenses and other current assets 5,895 4,009
Total current assets 420,291 282,631
Property and equipment, net 7,132 5,794
Other assets 2,354 1,852
Restricted cash 806 906
Total assets $ 430,583 $ 291,183
Liabilities and stockholders equity
Current liabilities
Accounts payable $ 16,162 $ 21,887
Accrued liabilities and other 26,036 14,502
Total current liabilities 42,198 36,389
Long-term debt 138,140 19,740
Other long-term liabilities 1,211 462
Total liabilities 181,549 56,591
Stockholders equity
Common stock, $0.001 par value, 290,000,000 shares authorized,
28,886,862 and 28,143,573 shares issued and outstanding at
December 31, 2016 and 2015, respectively 29 28
Additional paid-in capital 470,869 424,147
Accumulated other comprehensive loss (678 ) (175 )
Accumulated deficit (221,186 ) (189,408 )
Total stockholders equity 249,034 234,592
Total liabilities and stockholders equity $ 430,583 $ 291,183
SOURCE Nevro Corp.

Nevro Reports Fourth Quarter and Full Year 2016 Financial Results and Provides 2017 Outlook

Uploaded by

Copyright:

Available Formats

Nevro Reports Fourth Quarter and Full Year 2016 Financial Results and Provides 2017 Outlook

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Nevro Reports Fourth Quarter and Full Year 2016 Financial Results and Provides 2017 Outlook

Uploaded by

Copyright:

Available Formats

Nevro Reports Fourth Quarter and Full Year 2016 Financial

Results and Provides 2017 Outlook

2016 Accomplishment & Highlights:

Fourth Quarter Financial Results

Revenue Guidance for Full Year 2017

Webcast and Conference Call Information

Investor Relations Contact:

Three Months Ended Year Ended

December 31, December 31,

SOURCE Nevro Corp.

You might also like